US Stock MarketDetailed Quotes

NKGN NKGEN BIOTECH

Watchlist

1.570
-0.070-4.27%

Close May 30 16:00 ET

1.530
-0.040-2.55%

Pre 07:46 ET

39.07MMarket Cap-414P/E (TTM)

NKGEN BIOTECH Stock Forum

TrendTrader

May 21 11:57

Over 1.85 can test 2, over 2 can test 2.5

$NKGEN BIOTECH(NKGN.US)$

Stock Region

May 21 11:00

Biotechnology Company Receives Clearance For Alzheimer's Treatment Development

NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease.
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapeutics, has announced a significant milestone. The company's cryopreserved autologous enhanced SN...

TrendTrader

May 21 10:16

Can test yesterday highs with volume.

$NKGEN BIOTECH(NKGN.US)$

TrendTrader

May 20 14:56

Great recovery! Can retest highs

$NKGEN BIOTECH(NKGN.US)$

TrendTrader

May 20 14:14

Recovering nicely. Over vwap can retest highs with volume

$NKGEN BIOTECH(NKGN.US)$

Stock Region

May 20 14:02

Global E-commerce Company Announces Subsidiary Partnership With SpaceX Satellite Reseller

NKGen Biotech's SNK01 NK Cell Therapy Cleared for Phase 2 Clinical Trial in Alzheimer's Disease.
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company, has announced that its innovative cryopreserved, autologous enhanced natural killer (NK) cell therapy, SNK01, has been cleared to progress into Phase 2 clinical development for the treatment of moderate Alzheimer’s disease. This advanceme...